Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.5 USD +1.63% Intraday chart for Allogene Therapeutics, Inc. -0.79% -22.12%
May. 31 Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target MT
May. 21 Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating
HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating
Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating
B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating
Allogene Therapeutics Prices $110 Million Offering
Transcript : Allogene Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Allogene Therapeutics: Q1 Earnings Snapshot
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene Therapeutics Announces Q2 Investor Conference Participation
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index
Allogene Therapeutics Files $500 Million Mixed Shelf
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. News Allogene Therapeutics, Inc.
  5. Other languages